{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/management/covid-19/","result":{"pageContext":{"chapter":{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19","depth":2,"htmlHeader":"<!-- begin field 0619eb5a-8a37-484e-9960-ab9c00bf705a --><h2>Scenario: COVID-19 Management</h2><!-- end field 0619eb5a-8a37-484e-9960-ab9c00bf705a -->","summary":"Covers management when considering the possibility of COVID-19.","htmlStringContent":"<!-- begin item a5514e57-4906-4d06-a574-ab9c00bf6fff --><!-- begin field 0a3a7b51-f474-4506-ba31-acbc015bb2c5 --><p>From age 18 years onwards.</p><!-- end field 0a3a7b51-f474-4506-ba31-acbc015bb2c5 --><!-- end item a5514e57-4906-4d06-a574-ab9c00bf6fff -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"067b6206-49ce-5ea5-ad43-95d2faca3712","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field bba7f567-7f83-4e21-9dfb-ab9c00bf705d --><h3>How should my management vary when considering the possibility of COVID-19?</h3><!-- end field bba7f567-7f83-4e21-9dfb-ab9c00bf705d -->","summary":null,"htmlStringContent":"<!-- begin item e98832e5-af90-449f-9ce7-ab9c00bf705d --><!-- begin field c25a7ac7-98b6-4b5c-bd9c-ab9c00bf705d --><p><strong>For people who have COVID-19 or suspected COVID-19:</strong></p><ul><li>You should be aware that people with psoriasis who are taking drugs that affect the immune system may have atypical presentations of COVIDâ€‘19. For example, patients taking prednisolone may not develop a fever.</li></ul><p><strong>For people with psoriasis who have COVID-19 or suspected infection and are using topical treatment they should:</strong></p><ul><li>Continue topical treatments.</li></ul><p><strong>For clinicians treating these people they should:</strong></p><ul><li>Think about treating new-onset dermatological conditions with topical treatments rather than new systemic treatments that affect the immune system.</li></ul><p><strong>For people with psoriasis who have COVID-19 or suspected infection and are taking systemic treatment they should:</strong></p><ul><li>Not suddenly stop any oral steroid medication.</li><li>Continue taking hydroxychloroquine, chloroquine, mepacrine, dapsone, and sulfasalazine.</li></ul><p><strong>For clinicians treating these people they should:</strong></p><ul><li>In discussion with their specialist consider temporarily stopping all other oral immunosuppressive therapies, novel small-molecule immunosuppressants, biological therapies, and monoclonal antibodies.</li><li>Then contact the specialist for advice on when to restart treatment.</li></ul><!-- end field c25a7ac7-98b6-4b5c-bd9c-ab9c00bf705d --><!-- end item e98832e5-af90-449f-9ce7-ab9c00bf705d -->","subChapters":[{"id":"884d835e-620d-5a80-aa00-f3a4c535751a","slug":"basis-for-recommendation-cd6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e6ace6bd-0586-4454-b921-ab9c00bf705f --><h4>Basis for recommendation</h4><!-- end field e6ace6bd-0586-4454-b921-ab9c00bf705f -->","summary":null,"htmlStringContent":"<!-- begin item cd6067a8-472d-4308-8a4e-ab9c00bf705f --><!-- begin field 8f075d6a-16aa-4aee-93c0-ab9c00bf705f --><p>These recommendations are based on <em>COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2020</a>].</p><!-- end field 8f075d6a-16aa-4aee-93c0-ab9c00bf705f --><!-- end item cd6067a8-472d-4308-8a4e-ab9c00bf705f -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}